Voleon Capital Management LP Purchases Shares of 56,354 Gilead Sciences, Inc. (NASDAQ:GILD)

Voleon Capital Management LP bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 56,354 shares of the biopharmaceutical company's stock, valued at approximately $5,205,000.

A number of other institutional investors have also made changes to their positions in GILD. Nicolet Advisory Services LLC increased its holdings in shares of Gilead Sciences by 2.9% in the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock valued at $322,000 after purchasing an additional 100 shares during the last quarter. Southland Equity Partners LLC lifted its position in Gilead Sciences by 3.6% during the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock worth $289,000 after acquiring an additional 110 shares during the last quarter. Berkshire Bank boosted its holdings in shares of Gilead Sciences by 3.4% during the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock worth $314,000 after acquiring an additional 111 shares during the period. CFO4Life Group LLC grew its position in shares of Gilead Sciences by 2.7% in the fourth quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company's stock valued at $394,000 after purchasing an additional 112 shares during the last quarter. Finally, Howe & Rusling Inc. lifted its holdings in Gilead Sciences by 2.5% during the 4th quarter. Howe & Rusling Inc. now owns 4,704 shares of the biopharmaceutical company's stock worth $435,000 after purchasing an additional 115 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have weighed in on GILD. Piper Sandler increased their price objective on Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. The Goldman Sachs Group lifted their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price on the stock. Bank of America lifted their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Finally, Oppenheimer reduced their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $110.55.

Gilead Sciences Trading Up 0.4 %

NASDAQ:GILD traded up $0.43 during mid-day trading on Friday, hitting $103.68. 7,032,975 shares of the company's stock were exchanged, compared to its average volume of 7,528,671. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $129.10 billion, a P/E ratio of 280.22, a PEG ratio of 0.71 and a beta of 0.26. The company has a 50 day simple moving average of $108.69 and a 200-day simple moving average of $98.82.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Gilead Sciences's revenue was down .3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.32) earnings per share. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 3.05%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio is presently 66.53%.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total value of $266,000.00. Following the transaction, the chief financial officer now directly owns 168,174 shares of the company's stock, valued at $17,893,713.60. The trade was a 1.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders sold 160,605 shares of company stock worth $16,718,136. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.